Wegovy and Zepbound Transform US Healthcare
Weight-loss drugs such as Wegovy and Zepbound are significantly reducing demand for bariatric surgeries and improving cardiovascular health among obese individuals. A study shows surgeries decreased by 34% while the use of GLP-1 medications increased by 140%. These medications not only promote weight loss but also lower the risk of adverse heart events, leading to changes in healthcare practices and potential cost savings. However, coverage and affordability remain issues, with some insurers and employers reducing or halting their support for these treatments.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)